MedImmune to Advance AgonOx’s OX40 Cancer Agonists in Global Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 11 (Table of Contents)
Published: 17 Nov-2011
DOI: 10.3833/pdr.v2011.i11.1615 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
AstraZeneca’s MedImmune has formed an exclusive global partnership with AgonOx to develop tumour-specific T-cell immunity stimulators for the potential treatment of cancer based on AgonOx’s OX40 platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS